SLIDE 46 Mergers and Acquisitions
Table: Merger ranking for fjrms in the chemicals and allied products sector (SIC-28).
Firm i Firm j
- Mkt. ia
- Mkt. j
- Pat. i
- Pat. j
di dj ∆W [%]b ∆WF [%]c ∆WN [%]d Rank WELFARE LOSS Daiichi Sankyo Co. Ltd. Schering-Plough Corp. 0.4590 0.6057 14 52847 5 1
0.0476
1 MorphoSys AG Daiichi Sankyo Co. Ltd. 0.0038 0.4590 20 14 4 5
0.0132
2 Vical Inc. Cephalon 0.0008 0.1005 170 810 1 1
0.3903
3 Galapagos NV Medarex Inc. 0.0025 0.0028 30 168 2 9
0.1017
4 Galapagos NV Coley Pharm. Group Inc. 0.0025 0.0012 30 125 2 1
0.2329
5 Infjnity Pharm. Inc. Alnylam Pharm. Inc. 0.0011 0.0015 44 114 4 3
0.0484
6 Icagen Biosite Inc. 0.0005 0.0177 423 182 1 3
0.3587
7 Clinical Data Inc. Renovis 0.0037 0.0006 9 58 4 1
0.3005
8 Clinical Data Inc. Curagen 0.0037 0.0023 9 174 4 3
0.0108
9 EntreMed Inc. AVI BioPharma Inc. 0.0004 0.0000 62 67 3 1
0.2734
10 WELFARE GAIN Isis Pharm. Inc. Takeda Pharm. Co. Ltd. 0.0014 0.6445 4472 19460 4 7 0.8643 0.3406
1 Cell Genesys Inc. Pfjzer Inc. 0.0001 2.7679 236 78061 5 15 0.8636 0.6395
2 Exelixis Pfjzer Inc. 0.0057 2.7679 58 78061 7 15 0.8235 0.5397
3 Dyax Corp Pfjzer Inc. 0.0007 2.7679 227 78061 6 15 0.7717 0.5548
4 Bristol-Myers Squibb Co. Novartis 1.0287 2.0691 22312 18924 6 15 0.7696 0.4889
5 Exelixis Takeda Pharm. Co. Ltd. 0.0057 0.6445 58 19460 7 7 0.7661 0.5511
6 Exelixis Novartis 0.0057 2.0691 58 18924 7 15 0.7637 0.5130
7 Genzyme Corp. Pfjzer Inc. 0.1830 2.7679 1116 78061 3 15 0.7441 0.4206
8 Medarex Inc. Allergan Inc. 0.0028 0.1759 168 6154 9 3 0.7441 0.3586
9 Medarex Inc. Amgen 0.0028 0.8193 168 6960 9 13 0.7411 0.7776
10
a Market share in the primary 3-digit sector in which the fjrm is operating. b The relative welfare change due to a merger of fjrms i and j is computed as ∆W = (
Eµϑ[Wi∪j(G, q)] − W (qobs, Gobs)) /W (qobs, Gobs), where qobs and Gobs denote the observed R&D expenditures and network, respectively.
c ∆WF denotes the relative welfare change due to a merger of fjrms assuming a fjxed network of R&D collaborations. d ∆WN denotes the relative welfare change due to a merger of fjrms in the absence of a network of R&D collaborations.
46/57